ATED Therapeutics

Company Overview

Snapshot

Founded in March 2022, ATED Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of diagnostics and therapeutics for central nervous system diseases.

Business overview

ATED Therapeutics is a Health Tech & Life Sciences company developing diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases. Its core product is an investigational transfer RNA fragment blood test designed to detect Parkinson’s earlier, monitor disease progression, and quantify response to deep brain stimulation. The company also develops two disease-modifying Parkinson’s drug candidates, serving the B2G and B2B markets within the Medical Devices and Diagnostics Devices sectors.

Company Intelligence Q&A

What is ATED Therapeutics' primary focus?

ATED Therapeutics focuses on developing diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases.

What is the company's lead product?

The company's lead product is an investigational transfer RNA fragment blood test intended to help detect Parkinson’s earlier, monitor disease progression, and quantify response to deep brain stimulation.

When was ATED Therapeutics founded?

ATED Therapeutics was founded in March 2022.

What markets does ATED Therapeutics serve?

ATED Therapeutics serves the B2G and B2B markets.

What is the current product stage of ATED Therapeutics?

ATED Therapeutics' products are currently in the R&D stage, developing an investigational transfer RNA fragment blood test and two disease-modifying Parkinson’s drug candidates.